{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:40:44Z","timestamp":1761896444569},"reference-count":22,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.3892\/ol.2016.5375","type":"journal-article","created":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T07:26:03Z","timestamp":1478762763000},"page":"5043-5051","source":"Crossref","is-referenced-by-count":10,"title":["Diagnostic and therapeutic approaches to multiple myeloma patients: \u2018Real-world\u2019 data from representative multicentre treatment surveys in Germany between 2008 and 2011"],"prefix":"10.3892","volume":"12","author":[{"given":"Thomas M.","family":"Moehler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Merz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Kellermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Knauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,11,10]]},"reference":[{"key":"key20180108111925_b1-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/annonc\/mdt509","article-title":"Hillengass Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents","volume":"25","author":"Merz","year":"2014","journal-title":"Ann Oncol"},{"key":"key20180108111925_b2-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1634\/theoncologist.2011-0391","article-title":"European perspective on multiple myeloma treatment strategies: Update following recent congresses","volume":"17","author":"Ludwig","year":"2012","journal-title":"Oncologist"},{"key":"key20180108111925_b3-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2013.293","article-title":"Durie International myeloma working group recommendations for global myeloma care","volume":"28","author":"Ludwig","year":"2014","journal-title":"Leukemia"},{"key":"key20180108111925_b4-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1634\/theoncologist.2011-0229","article-title":"Improvement in survival of older adults with multiple myeloma: Results of an updated period analysis of SEER data","volume":"16","author":"Pulte","year":"2011","journal-title":"Oncologist"},{"key":"key20180108111925_b5-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"key20180108111925_b6-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-540-85772-3_3","article-title":"Molecular pathogenesis of multiple myeloma: Chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment","volume":"183","author":"Klein","year":"2011","journal-title":"Recent Results Cancer Res"},{"key":"key20180108111925_b7-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2013.099358","article-title":"European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma","volume":"99","author":"Engelhardt","year":"2014","journal-title":"Haematologica"},{"key":"key20180108111925_b8-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1586\/era.12.42","article-title":"Novel anticancer agents for multiple myeloma: A review of the evidence for their therapeutic and economic value","volume":"12","author":"Gaultney","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20180108111925_b9-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1159\/000321124","article-title":"How to treat multiple myeloma - a representative multicentre treatment survey","volume":"33","author":"Knauf","year":"2010","journal-title":"Onkologie"},{"key":"key20180108111925_b10-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"key20180108111925_b11-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108111925_b12-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1200\/JCO.2013.53.0329","article-title":"Combination of international scoring system 3, high lactate dehydrogenase and t (4;14) and\/or del (17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death","volume":"32","author":"Moreau","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20180108111925_b13-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"key":"key20180108111925_b14-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2014-03-561985","article-title":"The future of autologous stem cell transplantation in myeloma","volume":"124","author":"van Rhee","year":"2014","journal-title":"Blood"},{"key":"key20180108111925_b15-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108111925_b16-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"key20180108111925_b17-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1634\/theoncologist.2009-0203","article-title":"Current multiple myeloma treatment strategies with novel agents: A European perspective","volume":"15","author":"Ludwig","year":"2010","journal-title":"Oncologist"},{"key":"key20180108111925_b18-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20180108111925_b19-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"key":"key20180108111925_b20-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"key":"key20180108111925_b21-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: A meta-analysis of individual patient data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20180108111925_b22-ol-0-0-5375","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/cncr.28104","article-title":"Autologous retransplantation for patients with recurrent multiple myeloma: A single-center experience with 200 patients","volume":"119","author":"Sellner","year":"2013","journal-title":"Cancer"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2016.5375\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T06:35:13Z","timestamp":1601188513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2016.5375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,10]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,11,10]]},"published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.3892\/ol.2016.5375"],"URL":"https:\/\/doi.org\/10.3892\/ol.2016.5375","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,10]]}}}